Hypothyroidism in Thyroid Carcinoma Follow-up: Orlistat May Inhibit the Absorption of Thyroxine
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Effects of several additional medications on LT4 absorption have been documented in individual case reports.
“Effects of several additional medications have been documented in individual cases reports (148-151).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [150]
Based on data of the UK Medicines Information pharmacists, only two cases of interaction between orlistat and L-T4 were reported, most likely via T4 malabsorption; it was recommended that L-T4 and orlistat should be separated by 4 hours, and increased monitoring of thyroid hormone levels may be prudent.
“Based on data of the UK Medicines Information pharmacists (79), only two cases of interaction between orlistat and L-T4 were reported (80, 81), most likely via T4 malabsorption. It was recommended that L-T4 and orlistat “should be separated by 4 hours, and increased monitoring of […] thyroid hormone levels may be prudent” (79).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [80]
The citation lists haven’t been fetched yet
References 7 · Cited by 29
- Authors
- Madhava, K., & Hartley, A.
- Affiliations
- Queen Elizabeth Hospital Birmingham (GB)
- Corresponding author
- Madhava, K.
- ORCID
- Hartley, A.
- Venue
- Clinical Oncology
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 17
- Issue
- 6
- Pages
- 492
- ISSN
- 0936-6555 (ISSN-L)
- OpenAlex
- W2162630469
- Cited by
- 29
- References
- 7
- Citations by year
- 2025: 2 · 2023: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 4
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- orlistat, hypothyroidism, thyroid cancer, papillary thyroid carcinoma, TSH suppression therapy, obesity, adverse drug reactions
- MeSH terms
- Orlistat, Carcinoma, Papillary, Enzyme Inhibitors, Female, Humans, Hypothyroidism, Lactones, Lipase, Middle Aged, Thyroid Neoplasms, Thyroxine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
